National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014
Sarah Reagan-Steiner, David Yankey, Jenny Jeyarajah, Laurie D Elam-Evans, James A Singleton, C Robinette Curtis, Jessica MacNeil, Lauri E Markowitz, Shannon Stokley, Sarah Reagan-Steiner, David Yankey, Jenny Jeyarajah, Laurie D Elam-Evans, James A Singleton, C Robinette Curtis, Jessica MacNeil, Lauri E Markowitz, Shannon Stokley
Abstract
Routine immunization is recommended for adolescents aged 11-12 years by the Advisory Committee on Immunization Practices (ACIP) for protection against diseases including pertussis, meningococcal disease, and human papillomavirus (HPV)-associated cancers. To assess vaccination coverage among adolescents, CDC analyzed data collected regarding 20,827 adolescents through the 2014 National Immunization Survey-Teen (NIS-Teen). From 2013 to 2014, coverage among adolescents aged 13-17 years increased for all routinely recommended vaccines: from 84.7% to 87.6% for ≥1 tetanus-diphtheria-acellular pertussis (Tdap) vaccine dose, from 76.6% to 79.3% for ≥1 meningococcal conjugate (MenACWY) vaccine dose, from 56.7% to 60.0% and from 33.6% to 41.7% for ≥1 HPV vaccine dose among females and males, respectively.† Coverage differed by state and local area. Despite overall progress in vaccination coverage among adolescents, HPV vaccination coverage continues to lag behind Tdap and MenACWY coverage at state and national levels. Seven public health jurisdictions achieved significant increases in ≥1- or ≥3-dose HPV vaccination coverage among females in 2014, demonstrating that substantial improvement in HPV vaccination coverage is feasible.
Figures
References
- Strikas RA Advisory Committee on Immunization Practices (ACIP), ACIP Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years—United States, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:93–4.
- Petrosky E, Bocchini JA, Jr, Hariri S, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64:300–4.
- Elam-Evans LD, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2013. MMWR Morb Mortal Wkly Rep. 2014;63:625–33.
- National Institutes of Health. A report to the President of the United States from the President’s Cancer Panel. Bethesda, MD: National Institutes of Health; 2014. Uptake: urgency for action to prevent cancer. Available at .
- CDC. National and state vaccination coverage among adolescents aged 13–17 years—United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:685–93.
- Curtis CR. Increasing HPV vaccine coverage among adolescents: activities and lessons learned from 2013 PPHF projects. Presented at the 2014 National Immunization Conference; September 29–30, 2014; Atlanta, GA. Available at .
- Allison MA, Dunne EF, Markowitz LE, et al. HPV vaccination of boys in primary care practices. Acad Pediatr. 2013;13:466–74.
- Community Preventive Services Task Force. Guide to Community Preventive Services. Increasing appropriate vaccination. Available at .
- Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:608–12.
Source: PubMed